Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M1 positive allosteric modulator VU0467319 for Alzheimer’s disease: a single ascending-dose study in healthy participants

Abstract The development of cholinergic neurotransmitter based cognitive enhancers for Alzheimer’s disease and other neuropsychiatric disorders have focused recently on allosteric modulation of specific muscarinic acetylcholine receptor (mAChR) subtypes to reduce dose-limiting side-effects that have...

Полное описание

Библиографические подробности

Главные авторы:	Alexander C. Conley, Alexandra P. Key, Jennifer U. Blackford, Jason K. Russell, Kimberly M. Albert, Xuewen Gong, Michael Bubser, Jerri M. Rook, P. Jeffrey Conn, Craig W. Lindsley, Carrie K. Jones, Paul A. Newhouse
Формат:	Artigo
Язык:	Inglês
Опубликовано:	BMC 2025-07-01
Серии:	Alzheimer’s Research & Therapy
Предметы:	Muscarinic acetylcholine receptor subtype 1 (M1) Positive allosteric modulator (PAM) Cognition Metabolism Pharmacokinetics Pharmacodynamics
Online-ссылка:	https://doi.org/10.1186/s13195-025-01798-4
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!